U.S. Clinical Nutrition Market, By Type [Enteral Nutrition (Standard Nutrition and Disease Specific Nutrition) and Parenteral Nutrition (Amino Acids, Carbohydrates, Vitamins and Minerals and Others (Fibers, etc.)], By Form [Powder, Liquid and Others (Solid,etc.)], By Age Group [Infant Nutrition, Adult Nutrition and Geriatric Nutrition], By Application [Diabetes, Gastrointestinal Diseases, Cancer, Neurological Disorder, Metabolic Syndrome and Other (Critical Care, etc.)], and By End User [Hospitals, Home Care Setting, Long Term Care Facilities, Ambulatory Surgical Centers and Others (Research Institutes, etc.)] is estimated to be valued at US$ 4.93 Bn in 2023 and is expected to exhibit a CAGR of 6.3% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Market players are focusing on advancement of products by receiving funding from investors, and this is expected to drive the U.S clinical nutrition marketgrowth. For instance, in January 2022, Faeth Therapeutics, a U.S. based healthcare company that develops machine learning-driven precision nutrition solutions and treatment regimens to enhance cancer therapy, announced the closing of a US$ 20 Mnseed financing round co-led by Khosla Ventures and Future Ventures, with participation from S2G Ventures, Digitalis, KdT Ventures, Agfunder, Cantos, and Unshackled
Moreover, increasing product launches is also expected to drive the U.S clinical nutrition market growth over the forecast period For instance, on January 10, 2023, Cymbiotika, a U.S.- based leading nutritional supplement brand that is known for manufacturing pure, clinically-backed supplements, announced the launch of its product named Metabolic Health.
U.S. Clinical Nutrition Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
Factors such as investments by market players in research and development of novel medical nutritional products that targets COVID 19, and funding by various companies operating in the U.S. clinical nutrition market are expected to drive the market growth during the COVID 19 pandemic.
For instance, in May 2020, Danone’s nutrition health arm, Nutricia, a global multinational food-products corporation, granted US$ 1.1 Mnfor a global nutrition research program, a clinician-initiated research project in 16 countries across the world for defining guidelines of nutritional care for COVID-19 patients recovering from severe symptoms of COVID 19 and after discharge from intensive care unit (ICU).
U.S. Clinical Nutrition Market: Key Developments
In September 2022, Abbott, a global company developing innovative and science-based nutrition products, announced the launch of Similac GainSchool, the first and only milk formula with the PRODI-G Nutrient System and an exclusive blend of five different human milk oligosaccharides (HMOs) to support better brain connections, higher IQ, and stronger immunity.
In February 2022, Nestlé Health Science, a nutrition, health and wellness company, announced that the company had completed the acquisition of Vital Proteins, an U.S.-based collagen provider, and a lifestyle and wellness platform that offers supplements, beverages, and food products.
In February 2022, Kate Farms, a U.S.- based company that focuses on bringing plant-based nutrition into healthcare, announced the launch of its newest shake, Glucose Support 1.2. The plant-based, organic nutrition shake is developed to manage blood sugar as part of a balanced diet. Glucose Support 1.2 is developed to deliver meaningful plant-based nutrition to patients living with diabetes.
In April 2020, Gerber, a U.S.-based company specialized in early childhood nutrition, launched two A2 milk innovations including Gerber Good Start A2 Infant Formula and Good Start A2 Toddler Drink. Both products contained a combination of easy-to-digest A2 β-casein protein and probiotics & prebiotic HMO (Human Milk Oligosaccharide) to support digestive health of the baby.
Browse 15 Market Data Tables and 27 Figures spread through 145 Pages and in-depth TOC on “U.S. Clinical Nutrition Market”- Forecast to 2030, U.S. Clinical Nutrition Market, By Type [Enteral Nutrition (Standard Nutrition and Disease Specific Nutrition) and Parenteral Nutrition (Amino Acids, Carbohydrates, Vitamins and Minerals and Others (Fibers, etc.)], By Form [Powder, Liquid and Others (Solid,etc.)], By Age Group [Infant Nutrition, Adult Nutrition and Geriatric Nutrition], By Application [Diabetes, Gastrointestinal Diseases, Cancer, Neurological Disorder, Metabolic Syndrome and Other (Critical Care, etc.)], and By End User [Hospitals, Home Care Setting, Long Term Care Facilities, Ambulatory Surgical Centers and Others (Research Institutes, etc.)]
Link:
https://www.coherentmarketinsights.com/market-insight/us-clinical-nutrition-market-4412
Key Takeaways of the U.S. Clinical Nutrition Market:
U.S. clinical nutrition market is expected to exhibit a CAGR of 6.3% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the U.S. clinical nutrition market.
Among form, powder segment is expected to hold a dominant position in the U.S. clinical nutrition market during the forecast period dueto increasing launch of technologically advanced product by the market players. For instance, in April 2022, Seed Health, Inc., a U.S.-based microbial sciences company, launched its first pediatric innovation, PDS-08 Pediatric Daily Synbiotic, a clinically studied, two-in-one powdered synbiotic formula for children and adolescents (ages 3 to 17) with 9 probiotic strains and a fiber-based prebiotic. This launch followed Seed's award-winning flagship synbiotic for adults, DS-01 Daily Synbiotic, and extended the company's mission to employ the use of next generation of probiotics for the children's health market. PDS-08 is a clinically studied probiotic and prebiotic formulated with 9 probiotic strains, each with published dose-response data, and mixed-chain prebiotic fibers to support probiotic activity in the gastrointestinal tract (GI) tract. PDS-08 is also engineered to optimize probiotic survivability and stability through digestion, with delivery technology that safeguards the selected strains from enzymes, stomach acid, and bile salts. Key PDS-08TM clinical insights and formulation highlights include:
- Easy, frequent bowel movements, without stimulants
- Advanced respiratory health support
- Novel prebiotic to help bridge the fiber gap
- Increased ifidobacterium
Among end user, hospitals is expected to be the dominant in the U.S. clinical nutrition market, as hospitals are the major end users of U.S. clinical nutrition market, and these products are majorly used by every small, big, and multispecialty hospitals. Critically ill patients are admitted in hospitals for longer durations, in order to address their nutritional needs. Thus, growing number of hospitals and rising number of patients getting admitted every year in hospitals is expected to drive the market growth over the forecast period For instance, in 2022, according to a factsheet published by American Hospital Association, as per the survey conducted regarding number of hospitals in U.S., there were more than 6,093 hospitals in the U. S., in 2020, and total admissions in the U.S. hospitals were more than 33,356,853, in 2020.
Major players operating in the U.S. clinical nutrition market are Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Nestlé S.A., DANONE S.A., B. Braun Melsungen AG, Mead Johnson & Company LLC, Perrigo Company PLC., Leprino Foods Company, GSK plc., Sun Pharmaceutical Industries Ltd., Sanofi, BASF SE and DSM
